Guidelines for Stability Testing of Drug Products Under Extreme Conditions

1) Purpose

The purpose of this SOP is to provide a standardized procedure for conducting stability studies on drug products under extreme conditions. Stability testing ensures that drug products maintain their safety, efficacy, and quality when exposed to extreme temperatures, humidity, and light conditions.

2) Scope

This SOP applies to all drug products, including solid, liquid, and semi-solid formulations, produced or handled by the organization. It is intended for personnel involved in formulation development, quality control, and regulatory compliance.

3) Responsibilities

Formulation Scientist: Responsible for designing the stability study protocol and selecting appropriate extreme conditions and stability-indicating parameters.

Quality Control (QC) Team: Responsible for conducting stability tests according to the approved protocol and documenting results.

QA Team: Responsible for reviewing data, ensuring regulatory compliance, and approving the final stability report.

4) Procedure

4.1 Study Design:

1. Identify stability-indicating parameters (e.g., degradation, potency, moisture content, physical changes) relevant to the drug product.
2. Select appropriate analytical methods (e.g., HPLC, UV Spectroscopy, Karl Fischer Titration) to evaluate these parameters.
3. Define extreme conditions (e.g., 40°C/75% RH, freeze-thaw cycles, direct sunlight exposure) based on the product’s characteristics and regulatory guidelines.
4. Develop a study protocol outlining the objectives, sampling schedule, and analytical methods to be used under extreme conditions.

4.2 Sample Preparation:

1. Prepare samples from representative production batches and label them with batch numbers, storage conditions, and sampling time points.
2. Store samples in designated stability chambers with controlled extreme conditions as specified in the study protocol.

4.3 Testing Schedule:

1. Conduct initial testing on all samples to establish baseline data for the selected parameters.
2. Perform follow-up testing at predetermined intervals (e.g., 1 month, 3 months, 6 months) to monitor changes under extreme conditions.
3. Document all test results and analyze data for trends or deviations from acceptance criteria.

4.4 Data Analysis and Reporting:

1. Analyze data using statistical methods to determine trends and compliance with acceptance criteria.
2. Prepare a stability study report summarizing findings, conclusions, and recommendations for storage and handling under extreme conditions.
3. Submit the report for QA review and archiving.

5) Abbreviations, if any

QC: Quality Control

QA: Quality Assurance

HPLC: High-Performance Liquid Chromatography

6) Documents, if any

Extreme Condition Stability Protocol: Document detailing the study plan and methodology.

Analytical Data Records: Data sheets for all tests performed.

7) Reference, if any

ICH Q1A(R2): Stability Testing of New Drug Substances and Products

8) SOP Version

Version 1.0

Guidelines for Stability Testing of Temperature-Sensitive Biologics

1) Purpose

The purpose of this SOP is to provide a standardized procedure for conducting stability studies on temperature-sensitive biologics. Stability testing is necessary to ensure that these biologics maintain their safety, efficacy, and quality under various storage conditions throughout their shelf life.

2) Scope

This SOP applies to all temperature-sensitive biologic products, including vaccines, monoclonal antibodies, and other biologic formulations, produced or handled by the organization. It is intended for personnel involved in formulation development, quality control, and regulatory compliance.

3) Responsibilities

Formulation Scientist: Responsible for designing the stability study protocol and selecting appropriate stability-indicating parameters.

Quality Control (QC) Team: Responsible for conducting stability tests according to the approved protocol and documenting results.

QA Team: Responsible for reviewing data, ensuring regulatory compliance, and approving the final stability report.

4) Procedure

4.1 Study Design:

1. Identify stability-indicating parameters (e.g., potency, purity, sterility, aggregation) relevant to the temperature-sensitive biologic product.
2. Select appropriate analytical methods (e.g., HPLC, ELISA, SDS-PAGE) to evaluate these parameters.
3. Define storage conditions (e.g., refrigerated, frozen, controlled room temperature) based on the product’s characteristics and regulatory guidelines.
4. Develop a study protocol outlining the objectives, sampling schedule, and analytical methods to be used.

4.2 Sample Preparation:

1. Prepare samples from representative production batches and label them with batch numbers, storage conditions, and sampling time points.
2. Store samples in designated stability chambers under specified conditions.

4.3 Testing Schedule:

1. Conduct initial testing on all samples to establish baseline data for the selected parameters.
2. Perform follow-up testing at predetermined intervals (e.g., 1 month, 3 months, 6 months) to monitor changes in stability over time.
3. Document all test results and analyze data for trends or deviations from acceptance criteria.

4.4 Data Analysis and Reporting:

1. Analyze data using appropriate statistical methods to determine trends and compliance with acceptance criteria.
2. Prepare a stability study report summarizing findings, conclusions, and recommendations for storage and handling conditions.
3. Submit the report for QA review and archiving.

5) Abbreviations, if any

QC: Quality Control

QA: Quality Assurance

HPLC: High-Performance Liquid Chromatography

ELISA: Enzyme-Linked Immunosorbent Assay

SDS-PAGE: Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis

6) Documents, if any

Temperature-Sensitive Biologic Stability Protocol: Document detailing the study plan and methodology.

Analytical Data Records: Data sheets for all tests performed.

7) Reference, if any

ICH Q5C: Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products

8) SOP Version

Version 1.0

Guidelines for Stability Testing of Sterile Products

1) Purpose

The purpose of this SOP is to provide a standardized procedure for conducting stability studies on sterile products. Stability testing is essential to ensure that sterile products maintain their sterility, safety, efficacy, and quality under various storage conditions throughout their shelf life.

2) Scope

This SOP applies to all sterile products, including injectables, ophthalmics, and parenterals, produced or handled by the organization. It is intended for personnel involved in formulation development, quality control, and regulatory compliance.

3) Responsibilities

Formulation Scientist: Responsible for designing the stability study protocol and selecting appropriate stability-indicating parameters.

Quality Control (QC) Team: Responsible for conducting stability tests according to the approved protocol and documenting results.

QA Team: Responsible for reviewing data, ensuring regulatory compliance, and approving the final stability report.

4) Procedure

4.1 Study Design:

1. Identify stability-indicating parameters (e.g., sterility, particulate matter, pH, potency) relevant to the sterile product.
2. Select appropriate analytical methods (e.g., Sterility Testing, HPLC, Particle Size Analysis) to evaluate these parameters.
3. Define storage conditions (e.g., room temperature, refrigerated) based on the product’s characteristics and regulatory guidelines.
4. Develop a study protocol outlining the objectives, sampling schedule, and analytical methods to be used.

4.2 Sample Preparation:

1. Prepare samples from representative production batches and label them with batch numbers, storage conditions, and sampling time points.
2. Store samples in designated stability chambers under specified conditions.

4.3 Testing Schedule:

1. Conduct initial testing on all samples to establish baseline data for the selected parameters.
2. Perform follow-up testing at predetermined intervals (e.g., 1 month, 3 months, 6 months) to monitor changes in stability over time.
3. Document all test results and analyze data for trends or deviations from acceptance criteria.

4.4 Data Analysis and Reporting:

1. Analyze data using statistical methods to determine trends and compliance with acceptance criteria.
2. Prepare a stability study report summarizing findings, conclusions, and recommendations for storage and handling conditions.
3. Submit the report for QA review and archiving.

5) Abbreviations, if any

QC: Quality Control

QA: Quality Assurance

6) Documents, if any

Sterile Product Stability Protocol: Document detailing the study plan and methodology.

Analytical Data Records: Data sheets for all tests performed.

7) Reference, if any

ICH Q1A(R2): Stability Testing of New Drug Substances and Products

8) SOP Version

Version 1.0

Guidelines for Stability Testing of Enzyme-Based Drugs

1) Purpose

The purpose of this SOP is to provide a standardized procedure for conducting stability studies on enzyme-based drugs. Stability testing is essential to ensure that enzyme-based drugs maintain their activity, safety, efficacy, and quality throughout their shelf life under various storage conditions.

2) Scope

This SOP applies to all enzyme-based drugs, including therapeutic enzymes and diagnostic reagents, produced or handled by the organization. It is intended for personnel involved in formulation development, quality control, and regulatory compliance.

3) Responsibilities

Formulation Scientist: Responsible for designing the stability study protocol and selecting appropriate stability-indicating parameters.

Quality Control (QC) Team: Responsible for conducting stability tests according to the approved protocol and documenting results.

QA Team: Responsible for reviewing data, ensuring regulatory compliance, and approving the final stability report.

4) Procedure

4.1 Study Design:

1. Identify stability-indicating parameters (e.g., enzymatic activity, purity, degradation products) relevant to the enzyme-based drug.
2. Select appropriate analytical methods (e.g., Activity Assays, HPLC, SDS-PAGE) to evaluate these parameters.
3. Define storage conditions (e.g., refrigerated, frozen) based on the product’s characteristics and regulatory guidelines.
4. Develop a study protocol outlining the objectives, sampling schedule, and analytical methods to be used.

4.2 Sample Preparation:

1. Prepare samples from representative production batches and label them with batch numbers, storage conditions, and sampling time points.
2. Store samples in designated stability chambers under specified conditions.

4.3 Testing Schedule:

1. Conduct initial testing on all samples to establish baseline data for the selected parameters.
2. Perform follow-up testing at predetermined intervals (e.g., 1 month, 3 months, 6 months) to monitor changes in stability over time.
3. Document all test results and analyze data for trends or deviations from acceptance criteria.

4.4 Data Analysis and Reporting:

1. Analyze data using statistical methods to determine trends and compliance with acceptance criteria.
2. Prepare a stability study report summarizing findings, conclusions, and recommendations for storage and handling conditions.
3. Submit the report for QA review and archiving.

5) Abbreviations, if any

QC: Quality Control

QA: Quality Assurance

SDS-PAGE: Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis

6) Documents, if any

Enzyme-Based Drug Stability Protocol: Document detailing the study plan and methodology.

Analytical Data Records: Data sheets for all tests performed.

7) Reference, if any

ICH Q5C: Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products

8) SOP Version

Version 1.0

Guidelines for Stability Testing of Drug Implants

1) Purpose

The purpose of this SOP is to provide a standardized procedure for conducting stability studies on drug implants. Stability testing is necessary to ensure that drug implants maintain their safety, efficacy, and quality under various storage conditions throughout their shelf life.

2) Scope

This SOP applies to all drug implants, including biodegradable and non-biodegradable formulations, produced or handled by the organization. It is intended for personnel involved in formulation development, quality control, and regulatory compliance.

3) Responsibilities

Formulation Scientist: Responsible for designing the stability study protocol and selecting appropriate stability-indicating parameters.

Quality Control (QC) Team: Responsible for conducting stability tests according to the approved protocol and documenting results.

QA Team: Responsible for reviewing data, ensuring regulatory compliance, and approving the final stability report.

4) Procedure

4.1 Study Design:

1. Identify stability-indicating parameters (e.g., degradation rate, potency, sterility, and mechanical integrity) relevant to the drug implant.
2. Select appropriate analytical methods (e.g., HPLC, Mechanical Testing, Sterility Testing) to evaluate these parameters.
3. Define storage conditions (e.g., room temperature, refrigerated) based on the product’s characteristics and regulatory guidelines.
4. Develop a study protocol outlining the objectives, sampling schedule, and analytical methods to be used.

4.2 Sample Preparation:

1. Prepare samples from representative production batches and label them with batch numbers, storage conditions, and sampling time points.
2. Store samples in designated stability chambers under specified conditions.

4.3 Testing Schedule:

1. Conduct initial testing on all samples to establish baseline data for the selected parameters.
2. Perform follow-up testing at predetermined intervals (e.g., 1 month, 3 months, 6 months) to monitor changes in stability over time.
3. Document all test results and analyze data for trends or deviations from acceptance criteria.

4.4 Data Analysis and Reporting:

1. Analyze data using statistical methods to determine trends and compliance with acceptance criteria.
2. Prepare a stability study report summarizing findings, conclusions, and recommendations for storage and handling conditions.
3. Submit the report for QA review and archiving.

5) Abbreviations, if any

QC: Quality Control

QA: Quality Assurance

HPLC: High-Performance Liquid Chromatography

6) Documents, if any

Drug Implant Stability Protocol: Document detailing the study plan and methodology.

Analytical Data Records: Data sheets for all tests performed.

7) Reference, if any

ICH Q1A(R2): Stability Testing of New Drug Substances and Products

8) SOP Version

Version 1.0

Guidelines for Stability Testing of Temperature-Sensitive Biologics

1) Purpose

The purpose of this SOP is to provide a standardized procedure for conducting stability studies on temperature-sensitive biologics. Stability testing is necessary to ensure that these biologics maintain their safety, efficacy, and quality under various storage conditions throughout their shelf life.

2) Scope

This SOP applies to all temperature-sensitive biologic products, including vaccines, monoclonal antibodies, and other biologic formulations, produced or handled by the organization. It is intended for personnel involved in formulation development, quality control, and regulatory compliance.

3) Responsibilities

Formulation Scientist: Responsible for designing the stability study protocol and selecting appropriate stability-indicating parameters.

Quality Control (QC) Team: Responsible for conducting stability tests according to the approved protocol and documenting results.

QA Team: Responsible for reviewing data, ensuring regulatory compliance, and approving the final stability report.

4) Procedure

4.1 Study Design:

1. Identify stability-indicating parameters (e.g., potency, purity, sterility, aggregation) relevant to the temperature-sensitive biologic product.
2. Select appropriate analytical methods (e.g., HPLC, ELISA, SDS-PAGE) to evaluate these parameters.
3. Define storage conditions (e.g., refrigerated, frozen, controlled room temperature) based on the product’s characteristics and regulatory guidelines.
4. Develop a study protocol outlining the objectives, sampling schedule, and analytical methods to be used.

4.2 Sample Preparation:

1. Prepare samples from representative production batches and label them with batch numbers, storage conditions, and sampling time points.
2. Store samples in designated stability chambers under specified conditions.

4.3 Testing Schedule:

1. Conduct initial testing on all samples to establish baseline data for the selected parameters.
2. Perform follow-up testing at predetermined intervals (e.g., 1 month, 3 months, 6 months) to monitor changes in stability over time.
3. Document all test results and analyze data for trends or deviations from acceptance criteria.

4.4 Data Analysis and Reporting:

1. Analyze data using appropriate statistical methods to determine trends and compliance with acceptance criteria.
2. Prepare a stability study report summarizing findings, conclusions, and recommendations for storage and handling conditions.
3. Submit the report for QA review and archiving.

5) Abbreviations, if any

QC: Quality Control

QA: Quality Assurance

HPLC: High-Performance Liquid Chromatography

ELISA: Enzyme-Linked Immunosorbent Assay

SDS-PAGE: Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis

6) Documents, if any

Temperature-Sensitive Biologic Stability Protocol: Document detailing the study plan and methodology.

Analytical Data Records: Data sheets for all tests performed.

7) Reference, if any

ICH Q5C: Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products

8) SOP Version

Version 1.0

Guidelines for Stability Testing of Drug Products Under Extreme Conditions

1) Purpose

The purpose of this SOP is to provide a standardized procedure for conducting stability studies on drug products under extreme conditions. Stability testing ensures that drug products maintain their safety, efficacy, and quality when exposed to extreme temperatures, humidity, and light conditions.

2) Scope

This SOP applies to all drug products, including solid, liquid, and semi-solid formulations, produced or handled by the organization. It is intended for personnel involved in formulation development, quality control, and regulatory compliance.

3) Responsibilities

Formulation Scientist: Responsible for designing the stability study protocol and selecting appropriate extreme conditions and stability-indicating parameters.

Quality Control (QC) Team: Responsible for conducting stability tests according to the approved protocol and documenting results.

QA Team: Responsible for reviewing data, ensuring regulatory compliance, and approving the final stability report.

4) Procedure

4.1 Study Design:

1. Identify stability-indicating parameters (e.g., degradation, potency, moisture content, physical changes) relevant to the drug product.
2. Select appropriate analytical methods (e.g., HPLC, UV Spectroscopy, Karl Fischer Titration) to evaluate these parameters.
3. Define extreme conditions (e.g., 40°C/75% RH, freeze-thaw cycles, direct sunlight exposure) based on the product’s characteristics and regulatory guidelines.
4. Develop a study protocol outlining the objectives, sampling schedule, and analytical methods to be used under extreme conditions.

4.2 Sample Preparation:

1. Prepare samples from representative production batches and label them with batch numbers, storage conditions, and sampling time points.
2. Store samples in designated stability chambers with controlled extreme conditions as specified in the study protocol.

4.3 Testing Schedule:

1. Conduct initial testing on all samples to establish baseline data for the selected parameters.
2. Perform follow-up testing at predetermined intervals (e.g., 1 month, 3 months, 6 months) to monitor changes under extreme conditions.
3. Document all test results and analyze data for trends or deviations from acceptance criteria.

4.4 Data Analysis and Reporting:

1. Analyze data using statistical methods to determine trends and compliance with acceptance criteria.
2. Prepare a stability study report summarizing findings, conclusions, and recommendations for storage and handling under extreme conditions.
3. Submit the report for QA review and archiving.

5) Abbreviations, if any

QC: Quality Control

QA: Quality Assurance

HPLC: High-Performance Liquid Chromatography

6) Documents, if any

Extreme Condition Stability Protocol: Document detailing the study plan and methodology.

Analytical Data Records: Data sheets for all tests performed.

7) Reference, if any

ICH Q1A(R2): Stability Testing of New Drug Substances and Products

8) SOP Version

Version 1.0

Guidelines for Stability Testing of Temperature-Sensitive Biologics

1) Purpose

The purpose of this SOP is to provide a standardized procedure for conducting stability studies on temperature-sensitive biologics. Stability testing is necessary to ensure that these biologics maintain their safety, efficacy, and quality under various storage conditions throughout their shelf life.

2) Scope

This SOP applies to all temperature-sensitive biologic products, including vaccines, monoclonal antibodies, and other biologic formulations, produced or handled by the organization. It is intended for personnel involved in formulation development, quality control, and regulatory compliance.

3) Responsibilities

Formulation Scientist: Responsible for designing the stability study protocol and selecting appropriate stability-indicating parameters.

Quality Control (QC) Team: Responsible for conducting stability tests according to the approved protocol and documenting results.

QA Team: Responsible for reviewing data, ensuring regulatory compliance, and approving the final stability report.

4) Procedure

4.1 Study Design:

1. Identify stability-indicating parameters (e.g., potency, purity, sterility, aggregation) relevant to the temperature-sensitive biologic product.
2. Select appropriate analytical methods (e.g., HPLC, ELISA, SDS-PAGE) to evaluate these parameters.
3. Define storage conditions (e.g., refrigerated, frozen, controlled room temperature) based on the product’s characteristics and regulatory guidelines.
4. Develop a study protocol outlining the objectives, sampling schedule, and analytical methods to be used.

4.2 Sample Preparation:

1. Prepare samples from representative production batches and label them with batch numbers, storage conditions, and sampling time points.
2. Store samples in designated stability chambers under specified conditions.

4.3 Testing Schedule:

1. Conduct initial testing on all samples to establish baseline data for the selected parameters.
2. Perform follow-up testing at predetermined intervals (e.g., 1 month, 3 months, 6 months) to monitor changes in stability over time.
3. Document all test results and analyze data for trends or deviations from acceptance criteria.

4.4 Data Analysis and Reporting:

1. Analyze data using appropriate statistical methods to determine trends and compliance with acceptance criteria.
2. Prepare a stability study report summarizing findings, conclusions, and recommendations for storage and handling conditions.
3. Submit the report for QA review and archiving.

5) Abbreviations, if any

QC: Quality Control

QA: Quality Assurance

HPLC: High-Performance Liquid Chromatography

ELISA: Enzyme-Linked Immunosorbent Assay

SDS-PAGE: Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis

6) Documents, if any

Temperature-Sensitive Biologic Stability Protocol: Document detailing the study plan and methodology.

Analytical Data Records: Data sheets for all tests performed.

7) Reference, if any

ICH Q5C: Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products

8) SOP Version

Version 1.0

Guidelines for Stability Testing of Sterile Products

1) Purpose

The purpose of this SOP is to provide a standardized procedure for conducting stability studies on sterile products. Stability testing is essential to ensure that sterile products maintain their sterility, safety, efficacy, and quality under various storage conditions throughout their shelf life.

2) Scope

This SOP applies to all sterile products, including injectables, ophthalmics, and parenterals, produced or handled by the organization. It is intended for personnel involved in formulation development, quality control, and regulatory compliance.

3) Responsibilities

Formulation Scientist: Responsible for designing the stability study protocol and selecting appropriate stability-indicating parameters.

Quality Control (QC) Team: Responsible for conducting stability tests according to the approved protocol and documenting results.

QA Team: Responsible for reviewing data, ensuring regulatory compliance, and approving the final stability report.

4) Procedure

4.1 Study Design:

1. Identify stability-indicating parameters (e.g., sterility, particulate matter, pH, potency) relevant to the sterile product.
2. Select appropriate analytical methods (e.g., Sterility Testing, HPLC, Particle Size Analysis) to evaluate these parameters.
3. Define storage conditions (e.g., room temperature, refrigerated) based on the product’s characteristics and regulatory guidelines.
4. Develop a study protocol outlining the objectives, sampling schedule, and analytical methods to be used.

4.2 Sample Preparation:

1. Prepare samples from representative production batches and label them with batch numbers, storage conditions, and sampling time points.
2. Store samples in designated stability chambers under specified conditions.

4.3 Testing Schedule:

1. Conduct initial testing on all samples to establish baseline data for the selected parameters.
2. Perform follow-up testing at predetermined intervals (e.g., 1 month, 3 months, 6 months) to monitor changes in stability over time.
3. Document all test results and analyze data for trends or deviations from acceptance criteria.

4.4 Data Analysis and Reporting:

1. Analyze data using statistical methods to determine trends and compliance with acceptance criteria.
2. Prepare a stability study report summarizing findings, conclusions, and recommendations for storage and handling conditions.
3. Submit the report for QA review and archiving.

5) Abbreviations, if any

QC: Quality Control

QA: Quality Assurance

6) Documents, if any

Sterile Product Stability Protocol: Document detailing the study plan and methodology.

Analytical Data Records: Data sheets for all tests performed.

7) Reference, if any

ICH Q1A(R2): Stability Testing of New Drug Substances and Products

8) SOP Version

Version 1.0

Guidelines for Stability Testing of Enzyme-Based Drugs

1) Purpose

The purpose of this SOP is to provide a standardized procedure for conducting stability studies on enzyme-based drugs. Stability testing is essential to ensure that enzyme-based drugs maintain their activity, safety, efficacy, and quality throughout their shelf life under various storage conditions.

2) Scope

This SOP applies to all enzyme-based drugs, including therapeutic enzymes and diagnostic reagents, produced or handled by the organization. It is intended for personnel involved in formulation development, quality control, and regulatory compliance.

3) Responsibilities

Formulation Scientist: Responsible for designing the stability study protocol and selecting appropriate stability-indicating parameters.

Quality Control (QC) Team: Responsible for conducting stability tests according to the approved protocol and documenting results.

QA Team: Responsible for reviewing data, ensuring regulatory compliance, and approving the final stability report.

4) Procedure

4.1 Study Design:

1. Identify stability-indicating parameters (e.g., enzymatic activity, purity, degradation products) relevant to the enzyme-based drug.
2. Select appropriate analytical methods (e.g., Activity Assays, HPLC, SDS-PAGE) to evaluate these parameters.
3. Define storage conditions (e.g., refrigerated, frozen) based on the product’s characteristics and regulatory guidelines.
4. Develop a study protocol outlining the objectives, sampling schedule, and analytical methods to be used.

4.2 Sample Preparation:

1. Prepare samples from representative production batches and label them with batch numbers, storage conditions, and sampling time points.
2. Store samples in designated stability chambers under specified conditions.

4.3 Testing Schedule:

1. Conduct initial testing on all samples to establish baseline data for the selected parameters.
2. Perform follow-up testing at predetermined intervals (e.g., 1 month, 3 months, 6 months) to monitor changes in stability over time.
3. Document all test results and analyze data for trends or deviations from acceptance criteria.

4.4 Data Analysis and Reporting:

1. Analyze data using statistical methods to determine trends and compliance with acceptance criteria.
2. Prepare a stability study report summarizing findings, conclusions, and recommendations for storage and handling conditions.
3. Submit the report for QA review and archiving.

5) Abbreviations, if any

QC: Quality Control

QA: Quality Assurance

SDS-PAGE: Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis

6) Documents, if any

Enzyme-Based Drug Stability Protocol: Document detailing the study plan and methodology.

Analytical Data Records: Data sheets for all tests performed.

7) Reference, if any

ICH Q5C: Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products

8) SOP Version

Version 1.0